ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: PO2346

Decreased CD28 Expression in Memory CD4+ T Cells in Children Awaiting Kidney Transplant Is Associated with Increased Expression of Senescence Markers

Session Information

Category: Pediatric Nephrology

  • 1700 Pediatric Nephrology

Authors

  • Duneton, Charlotte, Emory University, Atlanta, Georgia, United States
  • George, Roshan P., Emory University, Atlanta, Georgia, United States
  • Ford, Mandy L., Emory University, Atlanta, Georgia, United States
  • Winterberg, Pamela D., Emory University, Atlanta, Georgia, United States
Background

Despite improved patient and graft outcomes with CD28-CD80/86 costimulation blockade, increased early acute rejection has hindered the widespread use of CTLA-4Ig (belatacept) for kidney transplant. Our group has previously reported lower pre-transplant frequencies of CD28+ effector memory helper T cells (CD4+TEM CCR7- CD45RA-) with decreased functional capacity in adults that were subsequently free from early rejection on belatacept. We aimed to determine if a similar T cell phenotype is detectable in children awaiting kidney transplant.

Methods

We analyzed existing flow cytometry data of unstimulated blood cells collected from children on dialysis (n=30) or healthy children (n=18) and examined expression of markers of costimulation (CD28), senescence (CD57, PD1), activation (CD38) and cytotoxicity (Perforin, Granzyme B) on memory CD4+ T cells.

Results

None of the children had CD28+CD4+ TEM frequencies as low as those we have previously observed in adults that were rejection-free on belatacept. However, 8 children on dialysis (27%) had CD28+CD4+TEM frequencies below the minimum value observed in healthy children (Fig1A-B). Patients with this "stable-like" T cell phenotype had higher frequency of CD4+TEM cells bearing senescence markers (CD57+PD1+ Fig 1C) and cytolytic effectors (Granzyme B, Perforin, Fig 1D) but decreased activation markers (CD38+ Fig 1E).

Conclusion

Despite their young age and limited antigen experience, a subset of children on dialysis accumulate CD4+ TEM cells that have lost CD28 expression and bear markers suggestive of impaired function, a phenotype reminiscent of adults with decreased risk for early rejection on belatacept. The functional capacity of these cell populations in children needs further study.

Funding

  • NIDDK Support